Joseph W Owen1, Kathryn J Fowler2, Maria B Doyle3, Nael E Saad2, David C Linehan4, William C Chapman3. 1. University of Kentucky, Department of Radiology, United States. Electronic address: jwowen2@uky.edu. 2. Washington University, Department of Radiology, United States. 3. Washington University, Department of Surgery, United States. 4. University of Rochester, Department of Surgery, United States.
Abstract
BACKGROUND: Hepatobiliary contrast enhanced MRI is known to be the most sensitive imaging modality for detection of colorectal hepatic metastasis. To date no study has investigated the rate of disappearing lesions with gadoxetic acid MR (Eovist/Primovist), or characterized the pathologic response of lesions which disappear on gadoxetic acid MR. METHODS: Retrospective review of hepatic resections for colorectal metastases between 01/2008 and 01/2014 was performed to evaluated the rate of disappearance of lesions on gadoxetic acid MR and the rate of complete pathologic response in the lesions that disappear. "Disappearing lesions" were lesions on baseline imaging that were not identifiable on pre-operative Eovist MRI. Complete pathologic response was defined as no viable tumor on pathology or by lack of recurrence within 1 year. RESULTS: In 23 patients, 200 colorectal metastases were identified on baseline imaging. On pre-operative Eovist MR 77 of the 200 lesions (38.5%) were "disappearing" lesions. At surgical pathology or 1 year follow-up imaging, 42 of 77 lesions (55%) demonstrated viable tumor (21) or recurrence (21). Thirty of 77 lesions (39%) were nonviable at pathology (10) or without evidence of recurrence at 1 year (20). 5 lesions were indeterminate. DISCUSSION: Despite disappearance on Eovist MR imaging (the most sensitive available imaging modality), 38.5% of all colorectal metastases disappeared and of those, 55% were viable.
BACKGROUND:Hepatobiliary contrast enhanced MRI is known to be the most sensitive imaging modality for detection of colorectal hepatic metastasis. To date no study has investigated the rate of disappearing lesions with gadoxetic acid MR (Eovist/Primovist), or characterized the pathologic response of lesions which disappear on gadoxetic acid MR. METHODS: Retrospective review of hepatic resections for colorectal metastases between 01/2008 and 01/2014 was performed to evaluated the rate of disappearance of lesions on gadoxetic acid MR and the rate of complete pathologic response in the lesions that disappear. "Disappearing lesions" were lesions on baseline imaging that were not identifiable on pre-operative Eovist MRI. Complete pathologic response was defined as no viable tumor on pathology or by lack of recurrence within 1 year. RESULTS: In 23 patients, 200 colorectal metastases were identified on baseline imaging. On pre-operative Eovist MR 77 of the 200 lesions (38.5%) were "disappearing" lesions. At surgical pathology or 1 year follow-up imaging, 42 of 77 lesions (55%) demonstrated viable tumor (21) or recurrence (21). Thirty of 77 lesions (39%) were nonviable at pathology (10) or without evidence of recurrence at 1 year (20). 5 lesions were indeterminate. DISCUSSION: Despite disappearance on Eovist MR imaging (the most sensitive available imaging modality), 38.5% of all colorectal metastases disappeared and of those, 55% were viable.
Authors: L Weiss; E Grundmann; J Torhorst; F Hartveit; I Moberg; M Eder; C M Fenoglio-Preiser; J Napier; C H Horne; M J Lopez Journal: J Pathol Date: 1986-11 Impact factor: 7.996
Authors: A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti Journal: J Clin Oncol Date: 2000-08 Impact factor: 44.544
Authors: Rebecca C Auer; Rebekah R White; Nancy E Kemeny; Lawrence H Schwartz; Jinru Shia; Leslie H Blumgart; Ronald P Dematteo; Yuman Fong; William R Jarnagin; Michael I D'Angelica Journal: Cancer Date: 2010-03-15 Impact factor: 6.860
Authors: Marcus C B Tan; David C Linehan; William G Hawkins; Barry A Siegel; Steven M Strasberg Journal: J Gastrointest Surg Date: 2007-07-11 Impact factor: 3.452
Authors: Alice C Wei; Paul D Greig; David Grant; Bryce Taylor; Bernard Langer; Steven Gallinger Journal: Ann Surg Oncol Date: 2006-03-10 Impact factor: 5.344
Authors: Alan I Valderrama-Treviño; Baltazar Barrera-Mera; Jesús C Ceballos-Villalva; Eduardo E Montalvo-Javé Journal: Euroasian J Hepatogastroenterol Date: 2017-09-29
Authors: V Kepenekian; A Muller; P J Valette; P Rousset; M Chauvenet; G Phelip; T Walter; M Adham; O Glehen; G Passot Journal: BJS Open Date: 2019-02-22
Authors: Vincenza Granata; Roberta Fusco; Sergio Venanzio Setola; Antonio Avallone; Raffaele Palaia; Roberto Grassi; Francesco Izzo; Antonella Petrillo Journal: J Int Med Res Date: 2020-06 Impact factor: 1.671
Authors: Jack Martin; Angelica Petrillo; Elizabeth C Smyth; Nadeem Shaida; Samir Khwaja; H K Cheow; Adam Duckworth; Paula Heister; Raaj Praseedom; Asif Jah; Anita Balakrishnan; Simon Harper; Siong Liau; Vasilis Kosmoliaptsis; Emmanuel Huguet Journal: World J Clin Oncol Date: 2020-10-24